This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Endoscopy Sales Growth to Support BSX Stock Amid Fierce Competition
by Zacks Equity Research
Boston Scientific successfully continues its expansion of operations across different geographies outside the United States.
HOLX Stock Gains Following the Acquisition of Gynesonics
by Zacks Equity Research
Hologic completes the acquisition of Gynesonics, developer of the Sonata System, for approximately $350 million.
Reasons to Add Penumbra Stock to Your Portfolio Now
by Zacks Equity Research
PEN stays on investors' radars due to its strong Thrombectomy business and international growth plans.
Omnicell Gains 26.2% in a Year: What's Driving the Stock?
by Zacks Equity Research
OMCL's shares rise on the back of its XT Amplify program gaining market traction with its initial offerings. However, the unfavorable macroeconomic scenario is concerning.
EssilorLuxottica to Acquire Pulse Audition: Will the Stock Rise?
by Zacks Equity Research
ESLOY is set to acquire Pulse Audition, an AI-driven tech startup, to strengthen its position in the hearing solution space.
Top Stock Reports for UnitedHealth, Costco & IBM
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Costco Wholesale Corporation (COST) and International Business Machines Corporation (IBM), as well as a micro-cap stock Smith-Midland Corporation (SMID).
BVS Stock Gains Post Divestiture of Advanced Rehabilitation Business
by Zacks Equity Research
Bioventus aims to improve its focus and execution within its core businesses and enhance liquidity following the divestiture.
3 GARP Stocks That Investors Can Scoop Up for Maximum Returns
by Vasundhara Sawalka
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RMD, RJF and KBR are some stocks that hold promise.
Reasons to Retain Inari Medical Stock in Your Portfolio for Now
by Zacks Equity Research
NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.
ResMed Gains 37.8% in a Year: What's Driving the Stock?
by Zacks Equity Research
RMD's shares gain on the back of robust mask and device sales growth. However, the unfavorable macroeconomic scenario is concerning.
Reasons to Retain Phibro Stock in Your Portfolio Now
by Zacks Equity Research
PAHC's prospering Vaccine business sparks optimism for future growth. However, headwinds such as unfavorable foreign exchange might hamper the company's operations.
Reasons to Retain Medtronic Stock in Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about MDT due to its impressive Neuroscience portfolio. Yet, the dull macroeconomic scenario poses a concern to the company's margins.
McKesson Stock Declines Post Divestiture of Canada-Based Businesses
by Zacks Equity Research
MCK aims to focus on capital deployment and prioritize investments to strengthen its strategic oncology and biopharma growth platforms.
Here's Why You Should Retain HOLX Stock in Your Portfolio Now
by Zacks Equity Research
Hologic's strength in the Surgical wing instills optimism among investors. Yet, currency impacts raise concerns.
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Hold IART Stock in Your Portfolio Now
by Zacks Equity Research
Integra's growth within its Tissue Technologies business segment bolsters investors' confidence in the stock.
Here's Why ResMed (RMD) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Reasons to Retain AMED Stock in Your Portfolio Now
by Zacks Equity Research
Amedisys' expected merger with UnitedHealth Group's Optum brings optimism to investors. Yet, a dull macroeconomic condition adds to the worry.
Is CorMedix (CRMD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how CorMedix (CRMD) and ResMed (RMD) have performed compared to their sector so far this year.
Growing Biosimilars Business, New Partnerships Support ABT Stock
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now
by Zacks Equity Research
Veracyte's progress with key drivers and the strength in its diagnostics tests bring optimism to investors.
ZBH Stock to Benefit From Global Expansion Despite Macro Issues
by Zacks Equity Research
Zimmer Biomet is witnessing strong market share gains within reconstructive Knees and Hips in key geographies despite macroeconomic challenges.
Lucid Inks New Partnership With VITALExam: Stock to Gain?
by Zacks Equity Research
LUCD collaborates with VITALExam to enhance access to the EsoGuard Esophageal DNA Test. The partnership launches a fully contracted testing event for Tuscaloosa firefighters.
Here's Why You Should Add HAE Stock to Your Portfolio Now
by Zacks Equity Research
Strong prospects for the Plasma franchise and favorable solvency bode well for Haemonetics.
Reasons to Add GMED Stock to Your Portfolio Right Now
by Zacks Equity Research
Globus Medical's synergistic merger with NuVasive and a strong liquidity position bring optimism to investors.